Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02834182
Other study ID # PO16049
Secondary ID
Status Not yet recruiting
Phase N/A
First received June 24, 2016
Last updated July 12, 2016
Start date July 2016
Est. completion date June 2019

Study information

Verified date June 2016
Source CHU de Reims
Contact Arthur KALADJIAN
Email akaladjian@chu-reims.fr
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

Theory of mind (TOM), a main component of social cognition processes, refers to the capacity to infer one's own and other person's mental states. Deficits in social cognition are found in patients with schizophrenia and bipolar disorder. The purpose of this study is to compare the neurofunctional profiles of schizophrenic patients, bipolar patients and healthy participants during the performance of a TOM task. Results may help to understand the neural bases of the impairments in social cognition in schizophrenia and bipolar disorder, which may in turn help to propose potential new psychosocial therapeutic approaches in these disorders.


Description:

Theory of mind (TOM) refer to the cognitive ability to attribute mental states to others, which plays an essential role in social communications and interactions between individuals. In several recent papers, it was shown that TOM is impaired in schizophrenia and bipolar disorder. This impairment strongly affects the quality of life in patients suffering from these disorders. The investigators study aims to explore the neural correlates of TOM in schizophrenic and bipolar patients, in comparison with those of healthy participants. These studies will be conducted on 30 schizophrenic patients, 30 bipolar patients, and 60 healthy participants, matched on age and educational level to each patient group. The investigators expect that the study of combined behavioral (neuropsychological tests) and neuro-anatomical data will allow to understand the pathophysiology of the alteration of social cognition processes in these illnesses.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date June 2019
Est. primary completion date June 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

Patients :

- Men or women aged from 18 to 65 years-old, right-handed, with a diagnosis of bipolar -disorder or schizophrenia, according to the DSM-5 criteria

- Native French speaker

- No substantial change in treatment for 2 weeks preceding study enrollment

- Able to provide informed written and verbal consent

Healthy Controls :

- Men or women aged from 18 to 65 years-old, right-handed

- Native French speaker

- Able to provide informed written and verbal consent

Exclusion Criteria:

Patients :

- A recent alcohol and/or drug abuse or dependence (in the last six months)

- A significant general medical illness, including neurological disorders or head trauma

- A sensorial impairment uncorrected (visual and/or hearing)

- Contraindication to the use of MRI

- Persons under legal incapacity

- Persons who are not covered by national health insurance

Healthy Controls :

- Severe chronic psychiatric disorders including Bipolar disorder and schizophrenia

- Depression diagnostic according to DSM-5

- A personal or first-degree-relative history of bipolar disorder, schizophrenia or schizoaffective disorder according to DSM-5

- A recent alcohol and/or drug abuse or dependence (in the last six months)

- A significant general medical illness, including neurological disorders or head trauma

- A sensorial impairment uncorrected (visual and/or hearing)

- Contraindication to the use of MRI

- People particularly protected by the law

- Persons who are not covered by national health insurance

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Intervention

Behavioral:
IRMf

Mini International Neuropsychiatric Interview

Positive And Negative Syndrom Scale

Young Mania Rating Scale

Hamilton Depression Scale


Locations

Country Name City State
France Chu de Reims Reims

Sponsors (1)

Lead Sponsor Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neuropsychological test : Mini International Neuropsychiatric Interview (M.I.N.I.) Up to 15 days after inclusion No
Primary Young Mania Rating Scale Up to 15 days after inclusion No
Primary Hamilton Depression Scale Up to 15 days after inclusion No
Primary Scale for the Assessment for Thought, Language and Communication Up to 15 days after inclusion No